A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)

NCT00092079 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

652

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis
Vitamin D Deficiency

Interventions

DRUG: MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks

Sponsor

Merck Sharp & Dohme LLC